Zacks Investment Research on MSN
AbbVie down since Q4 earnings report: How to play the stock
AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4.
AbbVie posts better-than-expected earnings but revenue declines across certain business lines.
Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive. AbbVie is also an excellent dividend stock. 10 stocks we like better than ...
AbbVie Inc. (NYSE:ABBV) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) tops our list for being one of the most promising stocks. TheFly reported on ...
Now, it’s worth noting Stock Advisor’s total average return is 884 % — a market-crushing outperformance compared to 193% for ...
Despite AbbVie exceeding expectations for the last year and its forecast for 2026, its stock still fell in trading this morning as investors zeroed in on vulnerabilities in its tentpole drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results